These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 33139244)

  • 1. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.
    Sha D; Jin Z; Budczies J; Kluck K; Stenzinger A; Sinicrope FA
    Cancer Discov; 2020 Dec; 10(12):1808-1825. PubMed ID: 33139244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
    Merino DM; McShane LM; Fabrizio D; Funari V; Chen SJ; White JR; Wenz P; Baden J; Barrett JC; Chaudhary R; Chen L; Chen WS; Cheng JH; Cyanam D; Dickey JS; Gupta V; Hellmann M; Helman E; Li Y; Maas J; Papin A; Patidar R; Quinn KJ; Rizvi N; Tae H; Ward C; Xie M; Zehir A; Zhao C; Dietel M; Stenzinger A; Stewart M; Allen J;
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
    Strickler JH; Hanks BA; Khasraw M
    Clin Cancer Res; 2021 Mar; 27(5):1236-1241. PubMed ID: 33199494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB.
    Sung MT; Wang YH; Li CF
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
    Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
    Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
    Klempner SJ; Fabrizio D; Bane S; Reinhart M; Peoples T; Ali SM; Sokol ES; Frampton G; Schrock AB; Anhorn R; Reddy P
    Oncologist; 2020 Jan; 25(1):e147-e159. PubMed ID: 31578273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.
    Quy PN; Kanai M; Fukuyama K; Kou T; Kondo T; Yamamoto Y; Matsubara J; Hiroshima A; Mochizuki H; Sakuma T; Kamada M; Nakatsui M; Eso Y; Seno H; Masui T; Takaori K; Minamiguchi S; Matsumoto S; Muto M
    Oncologist; 2019 Dec; 24(12):e1401-e1408. PubMed ID: 31186376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.
    Stenzinger A; Allen JD; Maas J; Stewart MD; Merino DM; Wempe MM; Dietel M
    Genes Chromosomes Cancer; 2019 Aug; 58(8):578-588. PubMed ID: 30664300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.
    McNamara MG; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E
    Cancer Treat Rev; 2020 Sep; 89():102084. PubMed ID: 32738738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
    Valero C; Lee M; Hoen D; Zehir A; Berger MF; Seshan VE; Chan TA; Morris LGT
    JAMA Oncol; 2021 May; 7(5):739-743. PubMed ID: 33599686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.
    Zhang W; Wang R; Fang H; Ma X; Li D; Liu T; Chen Z; Wang K; Hao S; Yu Z; Chang Z; Na C; Wang Y; Bai J; Zhang Y; Chen F; Li M; Chen C; Wei L; Li J; Chang X; Qu S; Yang L; Huang J
    Clin Transl Med; 2021 May; 11(5):e415. PubMed ID: 34047470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing panel-based tumor mutational burden (TMB) measurement.
    Budczies J; Allgäuer M; Litchfield K; Rempel E; Christopoulos P; Kazdal D; Endris V; Thomas M; Fröhling S; Peters S; Swanton C; Schirmacher P; Stenzinger A
    Ann Oncol; 2019 Sep; 30(9):1496-1506. PubMed ID: 31268125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.
    Buchhalter I; Rempel E; Endris V; Allgäuer M; Neumann O; Volckmar AL; Kirchner M; Leichsenring J; Lier A; von Winterfeld M; Penzel R; Christopoulos P; Thomas M; Fröhling S; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 Feb; 144(4):848-858. PubMed ID: 30238975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
    Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
    ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens.
    Parikh K; Huether R; White K; Hoskinson D; Beaubier N; Dong H; Adjei AA; Mansfield AS
    JAMA Netw Open; 2020 Feb; 3(2):e200202. PubMed ID: 32108894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy.
    Golkaram M; Zhao C; Kruglyak K; Zhang S; Bilke S
    PLoS Comput Biol; 2020 Nov; 16(11):e1008332. PubMed ID: 33166276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges.
    Fancello L; Gandini S; Pelicci PG; Mazzarella L
    J Immunother Cancer; 2019 Jul; 7(1):183. PubMed ID: 31307554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples.
    Mankor JM; Paats MS; Groenendijk FH; Roepman P; Dinjens WNM; Dubbink HJ; Sleijfer S; ; Cuppen E; Lolkema MPJK
    Br J Cancer; 2020 Mar; 122(7):953-956. PubMed ID: 32094484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.